CR20230109A - Sistema de liberación de fármacos descongestivos y bilastina - Google Patents

Sistema de liberación de fármacos descongestivos y bilastina

Info

Publication number
CR20230109A
CR20230109A CR20230109A CR20230109A CR20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A
Authority
CR
Costa Rica
Prior art keywords
decongestant
bilastine
layer
delivery system
drug delivery
Prior art date
Application number
CR20230109A
Other languages
English (en)
Inventor
Negre José María Suñé
Pujol Francisco Gual
Carreras Manuel Roig
Moreno Patricia Marcianes
Cerdeiras Paloma Tato
Azpitarte Ignacio Ortega
Herrero Gonzalo Hernández
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CR20230109A publication Critical patent/CR20230109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral multicapa que comprende un núcleo matricial, que comprende un descongestivo y una combinación de al menos dos derivados de celulosa, una primera capa que comprende un derivado de celulosa y una segunda capa opcional que comprende bilastina. La presente invención proporciona una forma de dosificación oral que comprende un fármaco descongestivo y bilastina con un perfil reproducible caracterizado por una liberación controlada del descongestivo durante un periodo superior a doce horas y preferiblemente al menos 16 horas y una liberación inmediata de bilastina después de la administración oral. La invención contempla además usos médicos de la misma.
CR20230109A 2020-07-30 2021-07-29 Sistema de liberación de fármacos descongestivos y bilastina CR20230109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382701 2020-07-30
PCT/EP2021/071244 WO2022023463A1 (en) 2020-07-30 2021-07-29 Decongestant drug delivery system

Publications (1)

Publication Number Publication Date
CR20230109A true CR20230109A (es) 2023-05-11

Family

ID=72039495

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230109A CR20230109A (es) 2020-07-30 2021-07-29 Sistema de liberación de fármacos descongestivos y bilastina

Country Status (9)

Country Link
EP (1) EP4188339A1 (es)
CL (1) CL2023000262A1 (es)
CO (1) CO2023002166A2 (es)
CR (1) CR20230109A (es)
DO (1) DOP2023000017A (es)
EC (1) ECSP23010160A (es)
PE (1) PE20231844A1 (es)
PY (1) PY2162539A (es)
WO (1) WO2022023463A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230248667A1 (en) * 2022-02-04 2023-08-10 Aurobindo Pharma Ltd Extended release compositions of pseudoephedrine or its pharmaceutically acceptable salt thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
PL377479A1 (pl) * 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
MX2011005899A (es) 2011-06-03 2013-01-10 Senosiain S A De C V Lab Composicion farmacéutica con antihistamínico no sedante y combinaciones.
CN104000822A (zh) * 2014-06-10 2014-08-27 合肥医工医药有限公司 一种含有比拉斯汀的复方感冒药物组合物
MX2015003937A (es) * 2015-03-26 2016-09-26 Alparis Sa De Cv Composicion farmaceutica de antihistaminico no sedante e inmunosupresor antiinflamatorio.

Also Published As

Publication number Publication date
CL2023000262A1 (es) 2023-10-06
PY2162539A (es) 2022-02-15
ECSP23010160A (es) 2023-03-31
CO2023002166A2 (es) 2023-06-09
WO2022023463A1 (en) 2022-02-03
PE20231844A1 (es) 2023-11-21
EP4188339A1 (en) 2023-06-07
DOP2023000017A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
CA2934595C (en) Composition and method for aiding sleep
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
CN101534809A (zh) 取代的2-氨基1，2，3，4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
JP2016531913A (ja) 神経抑制性ケタミンの単層による経口投与
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
NO20043723L (no) Farmasoytisk doseringform for avgivese gjennom slimhinner
EP1849462A3 (en) A method of alleviating signs and symptons of Spasticity
CA3135877A1 (en) Transdermal medicament
AU2019101470B4 (en) Melatonin mini-tablets and method of manufacturing the same
NO20080244L (no) Doseringsstyring for prasugrel
CR20230109A (es) Sistema de liberación de fármacos descongestivos y bilastina
Akural et al. Effects of combination treatment with ketoprofen 100 mg+ acetaminophen 1000 mg on postoperative dental pain: a single-dose, 10-hour, randomized, double-blind, active-and placebo-controlled clinical trial
KR20090045149A (ko) 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제
BR0318535A (pt) composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
Sharma et al. Effect of gabapentin in postoperative pain, nausea and vomiting in patients undergoing laparoscopic cholecystectomy
US20080312166A1 (en) Reversal core pharmaceutical system and method
AR083893A1 (es) Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente
NO20032581L (no) Farmasöytisk formulering av gepiron for oral administrering
Atlas et al. Haloperidol for the treatment of ketamine-induced emergence delirium
Talati et al. Rotigotine.
Hodgson Cancer pain management in a hospital setting
James Chronopharmaceutical drug delivery system of anti-hypertensive drugs: process optimization and biopharmaceutical evaluation
Terman et al. Controlled release melatonin in a physiological washout profile
MXPA01001969A (es) Tableta de liberacion temporizada que comprende naproxen y pseudoefedrina.
Talati et al. Rotigotine: the first transdermal nonergot-derived dopamine agonist for the treatment of Parkinson disease [corrected][published erratum appears in FORMULARY 2008 Jan; 43 (1): 12].